Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model

• Published in: Molecules (Basel, Switzerland) Vol. 28; no. 2; p. 502
• Main Authors: Alqudah, Abdelrahim, Qnais, Esam Y, Wedyan, Mohammed A, Altaber, Sara, Bseiso, Yousra, Oqal, Muna, AbuDalo, Rawan, Alrosan, Khaled, Alrosan, Amjad Z, Bani Melhim, Suhad, Alqudah, Mohammad, Athamneh, Rabaa Y, Gammouh, Omar
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04-01-2023; MDPI
• Subjects: Animals; Blood Glucose; Carbohydrates; Chemical compounds; Cholesterol; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Type 2 - metabolism; Diet, High-Fat - adverse effects; Disease Models, Animal; Enzymes; Flavonoids; Gene expression; Glucose; Glucose - pharmacology; Glucose tolerance; High fat diet; Homeostasis; Hyperglycemia; Hypoglycemic Agents - therapeutic use; Inflammation; Inflammation - drug therapy; Insulin; Insulin resistance; Insulin Resistance - physiology; Interleukin 6; isorhamnetin; Kinases; Low density lipoprotein; Metabolism; Metformin; Mice; Muscles; Musculoskeletal system; Oxidation resistance; Oxidative Stress; Pharmacology; Protein expression; Proteins; Skeletal muscle; Soleus muscle; Streptozocin; Streptozocin - pharmacology; Triglycerides; isorhamnetin; inflammation; diabetes; insulin resistance; oxidative stress
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules28020502

Background: Isorhamnetin is a flavonoid that is found in medical plants. Several studies showed that isorhamnetin has anti-inflammatory and anti-obesity effects. This study aims to investigate the anti-diabetic effects of isorhamnetin in a high-fat diet and Streptozotocin-(HFD/STZ)-induced mice model of type 2 diabetes. Materials and Methods: Mice were fed with HFD followed by two consecutive low doses of STZ (40 mg/kg). HFD/STZ diabetic mice were treated orally with isorhamnetin (10 mg/kg) or (200 mg/kg) metformin for 10 days before sacrificing the mice and collecting plasma and soleus muscle for further analysis. Results: Isorhamnetin reduced the elevated levels of serum glucose compared to the vehicle control group (p < 0.001). Isorhamnetin abrogated the increase in serum insulin in the treated diabetic group compared to the vehicle control mice (p < 0.001). The homeostasis model assessment of insulin resistance (HOMA-IR) was decreased in diabetic mice treated with isorhamnetin compared to the vehicle controls. Fasting glucose level was significantly lower in diabetic mice treated with isorhamnetin during the intraperitoneal glucose tolerance test (IPGTT) (p < 0.001). The skeletal muscle protein contents of GLUT4 and p-AMPK-α were upregulated following treatment with isorhamnetin (p > 0.01). LDL, triglyceride, and cholesterol were reduced in diabetic mice treated with isorhamnetin compared to vehicle control (p < 0.001). Isorhamnetin reduced MDA, and IL-6 levels (p < 0.001), increased GSH levels (p < 0.001), and reduced GSSG levels (p < 0.05) in diabetic mice compared to vehicle control. Conclusions: Isorhamnetin ameliorates insulin resistance, oxidative stress, and inflammation. Isorhamnetin could represent a promising therapeutic agent to treat T2D.